These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2243355)

  • 1. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phospholipid layers in vitro.
    Kishore BK; Kállay Z; Lambricht P; Laurent G; Tulkens PM
    J Pharmacol Exp Ther; 1990 Nov; 255(2):867-74. PubMed ID: 2243355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids.
    Kishore BK; Lambricht P; Laurent G; Maldague P; Wagner R; Tulkens PM
    J Pharmacol Exp Ther; 1990 Nov; 255(2):875-85. PubMed ID: 1700819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid.
    Beauchamp D; Laurent G; Maldague P; Abid S; Kishore BK; Tulkens PM
    J Pharmacol Exp Ther; 1990 Nov; 255(2):858-66. PubMed ID: 2243354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin.
    Laurent G; Carlier MB; Rollman B; Van Hoof F; Tulkens P
    Biochem Pharmacol; 1982 Dec; 31(23):3861-70. PubMed ID: 7159463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of substrate organization on the activity and on the mechanism of gentamicin-induced inhibition of rat liver lysosomal phospholipase A1.
    Piret J; Kishore BK; Tulkens PM
    Biochem Pharmacol; 1992 Feb; 43(4):895-8. PubMed ID: 1540243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of acidic phospholipids on the activity of lysosomal phospholipases and on their inhibition induced by aminoglycoside antibiotics--II. Conformational analysis.
    Mingeot-Leclercq MP; Piret J; Tulkens PM; Brasseur R
    Biochem Pharmacol; 1990 Aug; 40(3):499-506. PubMed ID: 2383283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of renal membrane binding and nephrotoxicity of gentamicin by polyasparagine and polyaspartic acid in the rat.
    Williams PD; Hottendorf GH
    Res Commun Chem Pathol Pharmacol; 1985 Feb; 47(2):317-20. PubMed ID: 3838817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of acidic phospholipids on the activity of lysosomal phospholipases and on their inhibition by aminoglycoside antibiotics--I. Biochemical analysis.
    Mingeot-Leclercq MP; Piret J; Brasseur R; Tulkens PM
    Biochem Pharmacol; 1990 Aug; 40(3):489-97. PubMed ID: 2383282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides.
    Williams PD; Hottendorf GH; Bennett DB
    J Pharmacol Exp Ther; 1986 Jun; 237(3):919-25. PubMed ID: 3754895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-phospholipid interactions: role in aminoglycoside nephrotoxicity.
    Kaloyanides GJ
    Ren Fail; 1992; 14(3):351-7. PubMed ID: 1509168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyaspartic acid protects against gentamicin nephrotoxicity in the rat.
    Ramsammy LS; Josepovitz C; Lane BP; Kaloyanides GJ
    J Pharmacol Exp Ther; 1989 Jul; 250(1):149-53. PubMed ID: 2746494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative assessment of poly-L-aspartic and poly-L-glutamic acids as protectants against gentamicin-induced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats.
    Kishore BK; Ibrahim S; Lambricht P; Laurent G; Maldague P; Tulkens PM
    J Pharmacol Exp Ther; 1992 Jul; 262(1):424-32. PubMed ID: 1378098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of the macrolide azithromycin with phospholipids. I. Inhibition of lysosomal phospholipase A1 activity.
    Van Bambeke F; Montenez JP; Piret J; Tulkens PM; Courtoy PJ; Mingeot-Leclercq MP
    Eur J Pharmacol; 1996 Oct; 314(1-2):203-14. PubMed ID: 8957238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyaspartic acid inhibits gentamicin-induced perturbations of phospholipid metabolism.
    Ramsammy L; Josepovitz C; Lane B; Kaloyanides GJ
    Am J Physiol; 1990 Jun; 258(6 Pt 1):C1141-9. PubMed ID: 2360622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of gentamicin-induced nephrotoxicity by pyridoxal-5'-phosphate in the rat.
    Kacew S
    J Pharmacol Exp Ther; 1989 Jan; 248(1):360-6. PubMed ID: 2492342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of gentamicin nephrotoxicity by the concomitant administration of poly-l-aspartic acid and poly-l-asparagine in rats.
    Beauchamp D; Laurent G; Maldague P; Tulkens PM
    Arch Toxicol Suppl; 1986; 9():306-9. PubMed ID: 3468909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic amphiphilic drug-induced renal cortical lysosomal phospholipidosis: an in vivo comparative study with gentamicin and chlorphentermine.
    Kacew S
    Toxicol Appl Pharmacol; 1987 Dec; 91(3):469-76. PubMed ID: 3424375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of lysosomal phospholipases by aminoglycoside antibiotics: in vitro comparative studies.
    Carlier MB; Laurent G; Claes PJ; Vanderhaeghe HJ; Tulkens PM
    Antimicrob Agents Chemother; 1983 Mar; 23(3):440-9. PubMed ID: 6847172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium is a competitive inhibitor of gentamicin-renal membrane binding interactions and dietary calcium supplementation protects against gentamicin nephrotoxicity.
    Humes HD; Sastrasinh M; Weinberg JM
    J Clin Invest; 1984 Jan; 73(1):134-47. PubMed ID: 6690474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of kidney lysosomal phospholipase A1 by aminoglycosides is a novel variant of substrate depletion inhibition.
    Hostetler KY; Jellison EJ
    J Pharmacol Exp Ther; 1990 Jul; 254(1):188-91. PubMed ID: 2366181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.